Hypothesis

mTORC1 activation directly inhibits PXR transcriptional activity via S6K‑dependent phosphorylation of the coactivator SRC‑1, reducing expression of tight‑junction genes and mucus secretion. This creates a mechanistic link between the nutrient‑sensing "civilization" program and the microbiome‑driven barrier defense. Consequently, longevity interventions that suppress mTORC1 (e.g., rapamycin) should enhance PXR‑mediated barrier protection, but only when sufficient intestinal indole‑3‑propionic acid (IPA) is present to activate the receptor. In aged mice, rapamycin alone will improve markers of systemic aging yet fail to restore gut barrier function unless combined with IPA supplementation; conversely, IPA will not rescue barrier defects in mice lacking PXR in intestinal fibroblasts or epithelial cells.

Testable predictions

1. Phosphorylation assay – In vitro, recombinant S6K will phosphorylate SRC‑1 at serine residues predicted to disrupt its interaction with PXR, decreasing PXR‑driven luciferase activity in a dose‑dependent manner (source).
2. Cellular read‑out – Treating human colonic organoids with 100 nM rapamycin will increase p‑S6K levels and reduce PXR‑target gene expression (Occludin, Claudin‑4, ZO‑1) by ~40 % compared with vehicle; adding 50 µM IPA will restore target expression to baseline only when mTORC1 activity is inhibited (source).
3. In vivo experiment – Aged (20‑month) C57BL/6 mice will receive four treatments for 12 weeks: (a) control chow, (b) rapamycin‑encapsulated pellets (14 mg kg⁻¹ day⁻¹), (c) IPA‑supplemented water (5 mM), (d) rapamycin + IPA. Barrier integrity will be measured by FITC‑dextran permeability, mucus thickness, and transepithelial electrical resistance in colonic segments. We predict: rapamycin alone lowers p‑S6K but does not improve permeability; IPA alone modestly improves mucus; the combination normalizes permeability to youthful levels and extends median lifespan relative to controls.
4. Genetic validation – Using Villin‑Cre PXR^fl/fl (epithelial) and Col1a2‑Cre PXR^fl/fl (fibroblast) knockouts, the rapamycin + IPA regimen will fail to rescue barrier metrics in either knockout, confirming that PXR in both compartments is required for the protective effect (source).

Mechanistic reasoning

The seed idea frames mTOR as a "civilization‑versus‑survival dial." Here we specify the molecular switch: active mTORC1 phosphorylates SRC‑1, a coactivator that PXR relies on to drive transcription of barrier genes. When mTORC1 is on, SRC‑1 is phosphorylated, reducing its affinity for PXR, thus tilting the cell toward a survival phenotype (autophagy, stress resistance) at the expense of maintaining the multicellular barrier. Inhibition of mTORC1 removes this brake, allowing IPA‑bound PXR to recruit unphosphorylated SRC‑1 and reinforce tight‑junction complexes and mucus secretion. This explains why rapamycin extends lifespan yet often correlates with increased intestinal permeability in some studies—without sufficient IPA, the freed PXR cannot execute its barrier program.

Falsifiability

If rapamycin does not alter SRC‑1 phosphorylation status, or if IPA restores barrier function in PXR‑deficient mice, the hypothesis is refuted. Likewise, if the rapamycin + IPA combination fails to synergize in wild‑type aged animals, the proposed mTOR‑PXR crosstalk would be incorrect.